



Translating innovative ideas to breakthrough oncology medicines

CORPORATE PROFILE

IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, the Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by a Nobel Laureate and three Members of the National Academy of Sciences. IDEAYA is located in South San Francisco and La Jolla, California.

A major focus of IDEAYA is to exploit the concept of synthetic lethality, a phenomenon whereby the independent loss-of-function of two different genes have no significant effects on cell growth and viability, but when combined results in robust cell death. Synthetic lethality while a longstanding concept in genetic model systems and cancer biology has only recently been translated into a therapeutic reality with the approval of a PARP-inhibitor, olaparib, in BRCA deficient ovarian cancer. IDEAYA will focus on novel synthetic lethal interactions for genetically defined patient populations, exploiting inherent tumor susceptibilities en-route to discovery and development of small-molecule agents to treat major human cancers. Another area of focus for IDEAYA will be to exploit the potential of modulating DNA repair to augment response to immunotherapy. In addition, drug discovery programs will target pathways known to produce an immune suppressed tumor microenvironment, enabling tumors to escape recognition by the host immune system.

Leadership Team

Yujiro S. Hata, CEO
Jeffrey Hager, Ph.D., SVP Biology
Michael, P. Dillon, Ph.D., SVP Drug Discovery

Scientific Advisors

Alan D'Andrea, M.D., Harvard
John Petrini, Ph.D. MSKCC
Trey Ideker, Ph.D., UCSD
Stephen Kowalczykowski, Ph.D., UCD
Elizabeth Swisher, M.D., UW
Richard Ulevitch, Ph.D., Scripps
Chris Goodnow, Ph.D. Garvan
Laura Shawver, Ph.D., Cleave
Paul Reider, Ph.D., Princeton
Lawrence Fong, M.D., UCSF

Board Members

John Diekman, Ph.D., Chairman, 5AM
Tim Shannon, M.D., Canaan Partners
Terry Rosen, Ph.D., Arcus Biosciences
Jeff Stein, Ph.D., Cidara Therapeutics
Yujiro S. Hata, CEO, IDEAYA
Peter Worland, Ph.D., Celgene
Edward Hu, WuXi
Hannah Chang, M.D., Ph.D. 5AM

Investors

5AM Ventures
Canaan Partners
Celgene
WuXi Healthcare Ventures
Novartis Institutes of Biomedical Research
Alexandria Real Estate

Quick Facts

Founded August 2015
\$46M Series A

Contact Details

IDEAYA SSF
280 Utah Ave., Suite 250
South San Francisco, CA 94080

IDEAYA La Jolla
3033 Science Park Rd., Suite 250
San Diego, CA 92121

